Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on the Effectiveness of Lisaftoclax and Azacitidine in Adults with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition known as Higher Risk Myelodysplastic Syndrome (HR-MDS), which is a type of blood disorder where the bone marrow does not produce enough healthy blood cells. The study will evaluate the effectiveness of a new treatment combination involving two medications: Lisaftoclax (also known by its code name APG-2575) and Azacitidine. These medications will be compared to a combination of a placebo and Azacitidine to see which is more effective in treating HR-MDS.

The purpose of the study is to assess how well the combination of Lisaftoclax and Azacitidine works in patients who have been newly diagnosed with HR-MDS. Participants in the study will receive either the combination of Lisaftoclax and Azacitidine or a placebo with Azacitidine. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment until the study is completed. This helps ensure that the results are unbiased and reliable.

Throughout the study, participants will be monitored regularly to track their response to the treatment and any side effects they may experience. The study aims to provide valuable information on the potential benefits and safety of using Lisaftoclax in combination with Azacitidine for treating HR-MDS, which could lead to improved treatment options for patients with this condition in the future.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be randomly assigned to one of two groups. One group will receive the combination of lisaftoclax and azacitidine, while the other group will receive a placebo (a substance with no active medication) and azacitidine. This process is double-blind, meaning neither you nor the study team will know which group you are in.

  2. Step 2

    Medication administration

    If you are in the group receiving lisaftoclax, you will take it in the form of a tablet by mouth. The dosage and frequency will be determined by the study team based on your specific needs.

    All participants will receive azacitidine as a suspension for injection. This can be administered through a vein (intravenous), under the skin (subcutaneous), or into a muscle (intramuscular). The study team will decide the best method for you.

  3. Step 3

    Treatment duration

    The treatment will continue for a period specified by the study team, which may vary depending on your response to the medication and any side effects you experience. Regular assessments will be conducted to monitor your health and the effectiveness of the treatment.

  4. Step 4

    Follow-up visits

    You will have scheduled follow-up visits with the study team. During these visits, your health will be monitored, and any side effects or changes in your condition will be assessed. These visits are crucial for ensuring your safety and the success of the study.

  5. Step 5

    End of study participation

    At the end of your participation in the study, a final assessment will be conducted. This will include a review of your overall health and any changes that have occurred during the study. You will also have the opportunity to discuss your experience and any concerns with the study team.

Who can join the trial?

11 criteria

  • Must be 18 years old or older.
  • Must have a newly diagnosed higher risk myelodysplastic syndrome according to the 2022 World Health Organization classification.
  • Must have an ECOG performance status of 2 or less. (This is a scale used to assess how a disease affects a patient's daily living abilities, with 0 being fully active and 5 being deceased.)
  • Must have a life expectancy of at least 3 months.
  • Must be able to take oral medication.
  • Must have adequate organ function, which includes:
    • Creatinine clearance of at least 30 ml/min. (This measures how well the kidneys are working.)
    • Total bilirubin less than 1.5 times the upper limit of normal, except in certain conditions like Gilbert's syndrome or due to regular blood transfusions.
    • AST and ALT levels less than or equal to 2.5 times the upper limit of normal. (These are liver enzymes, and their levels indicate liver health.)
    • Women of childbearing potential must have a negative pregnancy test before starting the study. They and their partners must agree to use effective contraception during the study and for at least 6 months after the last dose.
    • Must be able to understand and sign a written informed consent form before any study procedures are done.
    • Must be willing to participate in the study and able to complete study procedures and follow-up examinations.

Who cannot join the trial?

10 criteria

  • Patients with any other type of cancer cannot participate.
  • Patients who have had a heart attack in the last 6 months are not eligible.
  • Patients with uncontrolled high blood pressure cannot join the study. Uncontrolled high blood pressure means that even with medication, the blood pressure is not within a safe range.
  • Patients with severe liver disease are excluded. Severe liver disease refers to serious conditions affecting the liver's ability to function properly.
  • Patients who are pregnant or breastfeeding cannot take part in the study.
  • Patients who are currently participating in another clinical trial are not eligible.
  • Patients with a known allergy to the study medication cannot participate.
  • Patients with a history of drug or alcohol abuse in the past year are excluded.
  • Patients with any serious infection that requires treatment with antibiotics are not eligible.
  • Patients with a history of certain mental health conditions, such as severe depression or anxiety, cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Lisaftoclax

    is a medication being studied for its potential to help treat a condition called higher risk myelodysplastic syndrome, which is a type of blood disorder. In this trial, Lisaftoclax is being tested to see if it can work together with another medication to improve treatment outcomes for patients who have been newly diagnosed with this condition.

  • Azacitidine

    is a medication that is already used to treat certain blood disorders, including myelodysplastic syndrome. It works by helping to restore normal growth and function to blood cells. In this trial, Azacitidine is being used in combination with Lisaftoclax to see if the two medications together can provide better results for patients with higher risk myelodysplastic syndrome.

What is already known about the treatment

Lisaftoclax – Lisaftoclax is administered orally and is currently being studied in combination with Azacitidine for its potential benefits in treating patients with newly diagnosed higher risk myelodysplastic syndrome (HR-MDS). This medication is in the clinical trial phase, specifically a global multicenter, double-blind, randomized Phase 3 study, which means it is being tested for safety and effectiveness before it can be approved for general medical use. Lisaftoclax works by targeting specific proteins in cancer cells, helping to stop their growth and survival. It is classified as a BCL-2 inhibitor, which is a type of drug that interferes with the proteins that help cancer cells live longer than they should.

Investigated diseases

Newly Diagnosed Higher Risk Myelodysplastic Syndrome – Myelodysplastic syndrome (MDS) is a group of disorders caused by poorly formed or dysfunctional blood cells. In higher risk MDS, the bone marrow produces immature blood cells that do not mature properly, leading to a shortage of healthy blood cells. This condition can result in symptoms such as fatigue, infections, and easy bruising or bleeding due to low blood cell counts. Over time, the disease can progress as the bone marrow becomes less effective at producing healthy cells. The condition is considered higher risk when there is a greater likelihood of progression to acute myeloid leukemia. The progression of the disease involves increasing bone marrow failure and worsening blood cell deficiencies.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-517247-31-00Protocol codeAPG2575MG301Estimated enrolment492 patientsSponsorAscentage Pharma Group Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.